May 13, 2025

Biopharmaceutical startup Avammune Therapeutics has secured $12 million in Series A funding co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I. The funding will support the clinical development of the lead asset AVA-NP-695, an ENPP1 inhibitor. Avammune, founded in 2020, focuses on developing small molecule immunotherapies to treat cancer and autoimmune disorders. The company's approach targets the innate immune system, offering a potentially more accessible and easier-to-administer alternative to existing immuno-oncology drugs.

Read More at Timesofindia →

Tags: Avammune therapeutics, Series a funding, Cancer therapies, Biopharmaceutical startup,